Background:
The present meta-analysis aimed to examine the effects of
sodium-glucose cotransporter 2 (SGLT2) inhibitors on the prognosis of diabetes
patients who experienced acute myocardial infarction (AMI). This investigation
encompassed an array of clinical endpoints, comprising cardiovascular death,
myocardial reinfarction, all-cause mortality, major adverse cardiovascular events
(MACEs), and rehospitalization.
Methods:
The study was conducted in
accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. The PubMed, Cochrane Library, Embase, and Web
of Science databases were searched up to October 2023. Studies reporting clinical
outcomes in diabetic patients who experienced AMI and were treated with SGLT2
inhibitors (SGLT2-I) were included. Two researchers independently selected the
studies and assessed the risk of bias in the included studies using the Cochrane
risk of bias tool for Risk for Bias In Non-randomized Studies-of Interventions
(ROBINS-I).
Results:
A total of 2450 publications were initially
retrieved; ultimately, five studies involving 5398 patients were included in the
meta-analysis. The analysis revealed that SGLT2-I were associated with
significantly lower risks of cardiovascular death (odds ratio (OR), 0.34; 95%
CI, 0.14–0.82) and all-cause mortality (OR, 0.54; 95% CI, 0.38–0.76). However,
SGLT2-I did not lead to a significant decrease in the rate of myocardial
reinfarction (OR, 0.91; 95% CI, 0.65–1.29). SGLT2-I did lead to a significant
reduction in MACEs (OR, 0.59; 95% CI, 0.35–1.0), but there was significant
heterogeneity among the included studies. SGLT2-I also led to a significant
reduction in rehospitalizations (OR, 0.45; 95% CI, 0.26–0.76). There was
significant heterogeneity in the analysis of rehospitalization, but the effect
remained significant when we excluded the main sources of heterogeneity (OR,
0.35; 95% CI, 0.24–0.52).
Conclusions:
The pooled analyses revealed
that SGLT2-I were associated with reductions in all-cause mortality,
cardiovascular death, and rehospitalization. In the future, prospective studies
with larger sample sizes are needed to confirm and refine these findings.